Jane Cullis is a science advisor in the firm’s Litigation Department and a member of its Intellectual Property practice. She contributes to the firm’s work in patent litigation, patent opinions and due diligence. Dr. Cullis joined the firm in 2019. She is an editor and contributor to the firm’s award-winning biosimilars blog, Big Molecule Watch.
Dr. Cullis obtained her Ph.D. in Medical Biophysics from the University of Toronto under the supervision of Dr. Robert Rottapel. Dr. Cullis’ thesis focused on deciphering signaling pathways regulated by the RAS oncogene, which is mutated in over 90% of pancreatic cancers. Dr. Cullis’ research identified the Rho guanine nucleotide exchange factor GEF-H1 as a critical amplifier of oncogenic signaling in animal models of pancreatic cancer. Dr. Cullis’ work was published in the journal Cancer Cell in 2014 and was awarded the Ontario Cancer Institute and Princess Margaret Hospital paper of the year.
Dr. Cullis continued her research in pancreatic cancer as a postdoctoral fellow at the New York University School of Medicine under the supervision of Dr. Dafna Bar-Sagi. There, Dr. Cullis identified a novel mechanism of action of the FDA-approved drug nanoparticle albumin-bound-paclitaxel (nab-paclitaxel, trade name Abraxane) on macrophages, the predominant immune cell type in pancreatic tumors. Dr. Cullis found that macrophages internalize and are activated by nab-paclitaxel, resulting in a tumor cell cytotoxic phenotype. Dr. Cullis’ work was featured on the cover of the journal Cancer Immunology Research in 2017, and NYU School of Medicine named Dr. Cullis Outstanding Postdoctoral Scholar of the Year.
Dr. Cullis was supported by the Ontario Graduate Scholarships in Science and Technology, Edward Dunlop Foundation Award (2007-2011), the McCuaig-Throop Bursary (2008), and the Ontario Student Opportunities Trust Fund Award (2007) from the University of Toronto throughout her graduate studies. Dr. Cullis’ postdoctoral research was funded by the Molecular Oncology and Immunology Training Grant (2013-2015) and the Immunology and Inflammation Training Grant (2016-2017) from the NYU School of Medicine.
In addition to Dr. Cullis’ research experience, she was co-founder and director of the NYU School of Medicine Women in Science group and serves as a science advisor on the research committee of the nonprofit organization for pancreatic cancer, Project Purple.
Contributor, “Guide to Biosimilars Litigation and Regulation in the U.S., 2019-2020 ed.,” published by Thomson Reuters, November 2019
Handler J, Cullis J, Vucic E, Avanzi A and Bar-Sagi D. Neoplastic pancreas cells enter a partially mesenchymal state with increased oncogenic potential following transient TGF-β exposure. Oncogene 2018 May.
Cullis J*, Das S* and Bar-Sagi D. Ras and Cancer in the 21st Century: Kras and Tumor Immunity: Friend or Foe? Cold Spring Harbor Perspectives in Medicine, Cold Spring Harbor Laboratory Press 2017 Dec.
Medrano M, Communal L, Brown KR, Iwanicki M, Normand J, Paterson J, Sircoulomb F, Krzyzanowski P, Novak M, Doodnauth SA, Saiz FS, Cullis J, Al-Awar R, Neel BG, McPherson J, Drapkin R, Ailles L, Mes-Massons AM, Rottapel R. Interrogation of Functional Cell-Surface Markers Identifies CD151 Dependency in High-Grade Serous Ovarian Cancer. Cell Reports 2017 Mar; 18(10): 2343-2358.
Cullis J, Siolas D, Avanzi A, Barui S, Maitra A, Bar-Sagi D. Macropinocytosis of nab-paclitaxel drives macrophage activation in pancreatic cancer. Cancer Immunol Res 2017 Mar; 5(3): 182- 190.
Cullis J*, Meiri D*, Sandi MJ, Radulovich N, Kent OA, Medrano M, Mokady D, Normand J, Larose J, Marcotte R, Marshall CB, Ikura M, Ketela T, Moffat J, Neel BG, Gingras AC, Tsao MS, Rottapel R. The RhoGEF GEF-H1 is required for oncogenic RAS signaling via KSR-1. Cancer Cell 2014 Feb; 25(2): 181-195.
*These authors contributed equally to this work.
Unsere Kunden verlassen sich auf unsere erstklassige Beratung, vor allem im Hinblick auf komplexe Transaktionen und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Branchen, verwenden wir einen kooperativen und interdisziplinären Ansatz, um Fragen unserer Kunden auch in extremen Spezialsituationen einer Lösung zuzuführen. Sie wollen mehr erfahren? Kontaktieren Sie uns gerne.
Nos équipes interviennent aux côtés de nos clients, industriels, fonds d’investissement, startups, institutions financières et dirigeants, dans le cadre de transactions et de contentieux complexes, et apportent des conseils de tout premier plan dans les secteurs financiers, des Sciences de la Vie, du Private Equity, de l’immobilier et des technologies. Nous traitons les dossiers juridiques de manière intègre, ingénieuse, souple et audacieuse pour répondre efficacement aux enjeux propres à chacun de nos clients, quels que soient la taille de l’opération et le secteur d’activité. Pour en savoir plus, contactez-nous.
客户信赖我们世界一流的咨询服务，希望获得针对复杂事务性工作与高风险诉讼的建议。我们通过协作式、跨领域的工作方法来解决客户最棘手的问题，涵盖金融、生命科学、私募股权、不动产和技术等多个行业。如需更多信息，请与我们联系。